Endocr Pract. 2017 Apr 2;23(4):432-441. doi: 10.4158/EP161517.OR. Epub 2017 Jan 17.
Variability in 25-hydroxyvitamin D (25(OH)D) change following vitamin D supplementation exists. Vitamin D metabolite measurement might assist in predicting 25(OH)D response and also contribute to defining vitamin D adequacy. This study assessed utility of vitamin D metabolite measurements to predict 25(OH)D response and explored the relationship between parathyroid hormone (PTH) and a "vitamin D composite index" comprised of the sum of serum 25(OH) D, cholecalciferol (vitamin D) and 24,25 dihydroxyvitamin D (24,25(OH)D).
Sixty-two postmenopausal women were randomized to daily vitamin D 1,800 IU or placebo for 4 months. Blood was drawn at baseline and after 1 and 4 months. Serum 25(OH)D, vitamin D, and 24,25(OH)D were measured by liquid chromatography tandem mass spectroscopy. Free 25(OH)D and PTH were measured by enzyme-linked immunosorbent assay. Repeated measures analysis of variance and regression analyses were performed.
Baseline 25(OH)D was positively correlated (P<.05) with vitamin D3, 24,25(OH)D and free 25(OH) D. Daily vitamin D supplementation increased all metabolites (P<.001). Substantial individual variability in 25(OH) D change at 4 months was observed but was unrelated to baseline vitamin D, 25(OH)D or 24,25(OH)D. Only body mass index, body weight, and body fat mass was associated with 25(OH)D change at 4 months. The vitamin D composite score was associated with serum PTH, but this association was similar to that observed with 25(OH) D alone.
This study does not support measurement of vitamin D metabolites in a composite index to assist in prediction of 25(OH)D response to supplementation. Overweight individuals have less robust 25(OH) D response to supplementation, but variability precludes prediction of the result following daily supplementation.
BMI = body mass index DXA = dual-energy X-ray absorptiometry LC-MS/MS = liquid chromatography tandem mass spectroscopy 25(OH)D = 25-hydroxyvitamin D 24,25(OH)D = 24,25 dihydroxyvitamin D PTH = parathyroid hormone vitamin D = cholecalciferol.
维生素 D 补充后 25-羟维生素 D(25(OH)D)的变化存在差异。维生素 D 代谢产物的测量可能有助于预测 25(OH)D 的反应,也有助于定义维生素 D 的充足性。本研究评估了维生素 D 代谢产物测量预测 25(OH)D 反应的效用,并探讨了甲状旁腺激素(PTH)与血清 25(OH)D、胆钙化醇(维生素 D)和 24,25 二羟维生素 D(24,25(OH)D)之和组成的“维生素 D 综合指数”之间的关系。
62 名绝经后妇女被随机分配每天服用维生素 D1800IU 或安慰剂 4 个月。在基线、1 个月和 4 个月时采血。血清 25(OH)D、维生素 D 和 24,25(OH)D 采用液相色谱串联质谱法测定。用酶联免疫吸附法测定游离 25(OH)D 和 PTH。采用重复测量方差分析和回归分析。
基线 25(OH)D 与维生素 D3、24,25(OH)D 和游离 25(OH)D 呈正相关(P<.05)。每日维生素 D 补充增加了所有代谢物(P<.001)。在 4 个月时,25(OH)D 的变化存在很大的个体差异,但与基线维生素 D、25(OH)D 或 24,25(OH)D 无关。只有体重指数、体重和体脂与 4 个月时的 25(OH)D 变化有关。维生素 D 综合评分与血清 PTH 相关,但与单独的 25(OH)D 相关。
本研究不支持测量维生素 D 代谢物组成的综合指数,以帮助预测补充 25(OH)D 的反应。超重个体对补充的 25(OH)D 反应较弱,但变异性排除了每日补充后的结果预测。
BMI = 体重指数 DXA = 双能 X 线吸收法 LC-MS/MS = 液相色谱串联质谱法 25(OH)D = 25-羟维生素 D 24,25(OH)D = 24,25 二羟维生素 D PTH = 甲状旁腺激素维生素 D = 胆钙化醇。